Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773798 | 0.73 | SIRT1 (0.31) | SIRT1 | |
| SCHEMBL4622623 | 0.71 | TRPA1 (0.33) | KMT2A | |
| SCHEMBL21617570 | 0.69 | MEN1 (0.55) | TSHRSIRT1MAPK1MEN1KMT2A | |
| SCHEMBL7938848 | 0.67 | KMT2A (0.40) | TSHRSIRT1MEN1KMT2ACYP2C19 | |
| SCHEMBL7594614 | 0.64 | ALDH1A1 (0.33) | TSHRSIRT1MEN1KMT2ACYP2C19 | |
| SCHEMBL3579154 | 0.63 | MEN1 (0.34) | TSHRSIRT1MEN1KMT2ACYP2C19 | |
| SCHEMBL17260882 | 0.62 | EPHX1 (0.36) | SIRT1MEN1KMT2ACYP2C19 | |
| SCHEMBL14673917 | 0.62 | HSD17B10 (0.39) | TSHRCYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL7129302 | 0.61 | MEN1 (0.33) | SIRT1MEN1KMT2ACYP2C19 | |
| SCHEMBL12362234 | 0.61 | NR1H2 (0.35) | TSHRSIRT1MEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112584-B2 | Nonsteroidal antiinflammatory agents | SCHERING AG (DE) | 2006-09-26 | — | — | US | disclosed |
| EP-1638945-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1572671-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005003098-A1 | HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | WO | disclosed |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | SCHERIN AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004058733-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES | TSHR 3390/4885SIRT1 1452/4885CYP3A4 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.